secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2022-11-18T23:59:59+00:00
Accession:  0001683168-22-007894
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte appoints Robert Weinstein to Board, removes cumulative voting
------------------------------------------------------------------------

- Robert Weinstein appointed to Board on Nov 14, 2022; chairs Audit Committee and will join Nominating Committee if elected at Dec 28, 2022 annual meeting.
- Interim CEO Joshua Silverman's month-to-month employment formalized; monthly salary set at $31,250.
- Bylaw amended to eliminate cumulative voting for directors; elections now decided by plurality vote.
- Board expanded from five to six members effective immediately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822007894/0001683168-22-007894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822007894/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-007894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer